Invivyd (IVVD) unusual large buyers for 7500 Sept $7.50 calls here at $1.10 up to $1.70 as IV spikes higher. Stock has been ramping higher since December after positive initial results from ongoing CANOPY phase 3 pivotal clinical trial investigating VYD222 for the prevention of COVID-19. IVVD is a $520M biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases. It delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). IVVD requested Emergency Use Authorization, EUA, from the U.S. Food and Drug Administration, FDA, for VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the pre-exposure prevention of COVID-19 in immunocompromised adults and adolescent based on positive initial results from the CANOPY Phase 3 pivotal clinical trial of VYD222, as well as ongoing in vitro neutralization activity against relevant variants such as JN.1. HCW raised its target to $15 recently assuming a 90% probability of success with potential 2H24 launch.